loratadine has been researched along with Stevens-Johnson Syndrome in 1 studies
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.
Stevens-Johnson Syndrome: Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.
Excerpt | Relevance | Reference |
---|---|---|
"We selected adverse drug reaction (ADR) reports on H1-antihistamines in children (0-16 years) up to June 2014 from VigiBase." | 1.46 | Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase. ( Biagi, C; Calamelli, E; Cipriani, F; Donati, M; Melis, M; Monaco, L; Motola, D; Ricci, G; Vaccheri, A, 2017) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Motola, D | 1 |
Donati, M | 1 |
Biagi, C | 1 |
Calamelli, E | 1 |
Cipriani, F | 1 |
Melis, M | 1 |
Monaco, L | 1 |
Vaccheri, A | 1 |
Ricci, G | 1 |
1 other study available for loratadine and Stevens-Johnson Syndrome
Article | Year |
---|---|
Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Cetirizine; Child; Child Mortality; Child, Pres | 2017 |